Aquestive Therapeutics, Inc.

Aquestive Therapeutics is a pharmaceutical company based in the United States that develops and commercializes products using its proprietary PharmFilm technology. The company offers several marketed products, including Libervant (a buccal soluble film of diazepam for seizures), Suboxone (sublingual film for opioid dependence), SYMPAZAN (oral soluble film of clobazam for epilepsy), KYNMOBI (sublingual film of apomorphine), and AZSTARYS (once-daily ADHD treatment). Its pipeline includes Anaphylm (epinephrine sublingual film in Phase 3 for allergic reactions) and AQST-108 (topical gel in Phase 2 for alopecia areata). The company also develops the Adrenaverse epinephrine prodrug platform.

Aquestive Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol AQST. The company's financials are reported in US dollars (USD), as it is headquartered in the United States. The NasdaqGM is a US-based exchange, and trading occurs in USD, making it accessible primarily to investors in the US market.

Aquestive Therapeutics operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company focuses on developing and manufacturing specialized pharmaceutical products, including both branded and generic drugs. Its specialty lies in creating innovative drug delivery technologies, such as oral soluble films, to address unmet medical needs in areas like central nervous system disorders and allergic reactions.

Aquestive Therapeutics is headquartered in Warren, New Jersey, United States. The company was incorporated in 2004 and primarily serves the US market, though it has a global presence. Its products are available in the United States and internationally, targeting patients with conditions such as seizures, opioid dependence, epilepsy, Parkinson's disease, ADHD, and allergic reactions. The company's pipeline also addresses alopecia areata.

Aquestive Therapeutics generates revenue by developing and commercializing pharmaceutical products using its proprietary PharmFilm technology, which enables drug delivery through oral soluble films. The company sells marketed products like Libervant, Suboxone, SYMPAZAN, KYNMOBI, and AZSTARYS, which address conditions such as seizures, opioid dependence, epilepsy, Parkinson's disease, and ADHD. It also earns revenue from licensing agreements and partnerships. Additionally, Aquestive invests in its pipeline, including Anaphylm for anaphylaxis and AQST-108 for alopecia areata, which may generate future revenue upon approval.